Skip to main content

Resmed Inc

RSMDF
Exchange
OTC
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0000943819

In the last 90 days, Resmed Inc insiders filed 0 open-market purchases and 5 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Other share classesRMD

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Resmed Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
5 filings
2 insiders, $5.26M in total
Insiders trading
2
Net value
−$5.26M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Resmed Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Resmed Inc
NameTitleLast reported holdingLast filingFilings, past year
Farrell Michael J.Chairman and CEO466,256Sep 10, 202615
Farrell Peter CDirector51,803Sep 4, 202611
Rider Michael JGlobal General Counsel9,488Jun 3, 20266
Sandercock BrettChief Financial Officer83,495May 4, 20269
De Witte JanDirector4,261Nov 26, 20253
Mowad-Nassar NicoleDirector777Nov 26, 20252
Taylor Ronald RDirector24,771Nov 24, 20251
Burt CarolDirector2,156Nov 24, 20251
Drexler KarenDirector10,602Nov 24, 20251
Gill HarjitDirector10,940Nov 24, 20252
Leong JustinChief Product Officer29,028Nov 24, 20251
DelOrefice ChristopherDirector2,423Nov 24, 20251
Tan DesneyDirector6,002Nov 24, 20251
Hernandez JohnDirector5,118Nov 24, 20251
Sulpizio RichardDirector17,796Nov 21, 20251
Ghoshal KaushikChief Commercial Officer, SaaS9,725Aug 5, 20250
Douglas Robert AndrewSpecial Advisor13,849Jan 3, 20240
Blaise LucilePresident, Sleep & RC Business10,305Nov 16, 20230
Pendarvis DavidChief Administrative Officer89,729Jun 30, 20230
Hollingshead JamesPresident, Sleep Business76,721Dec 1, 20210
Resmed IncDirector13,823Nov 22, 20210
Sodhi RajwantPresident, SaaS Business26,731Oct 14, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 10, 2026 (view filing)6:40 AM ETSep 82 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$222.44−$1.11M−1.1%466.3K after10b5-1
Sep 4, 2026 (view filing)6:30 AM ETSep 22 daysFarrell Peter CDirectorSSaleResMed Common Stock−970$234.73−$227.7K−1.8%51.8K after10b5-1
Aug 11, 2026 (view filing)6:30 AM ETAug 74 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$205.69−$1.03M−1.1%466.3K after10b5-1
Aug 6, 2026 (view filing)2:29 PM ETAug 51 dayFarrell Peter CDirectorSSaleResMed Common Stock−8.00K$225.00−$1.80M−13.2%52.8K after10b5-1
Jul 9, 2026 (view filing)7:40 AM ETJul 72 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$218.55−$1.09M−1.1%466.2K after10b5-1
Jun 9, 2026 (view filing)Jun 81 dayFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$193.96−$968.1K−1.1%466.3K after10b5-1
May 11, 2026 (view filing)May 74 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$207.82−$1.04M−1.1%466.2K after10b5-1
Apr 9, 2026 (view filing)Apr 72 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$225.50−$1.13M−1.1%466.2K after10b5-1
Apr 3, 2026 (view filing)Apr 12 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$224.31−$224.3K−1.2%83.5K after10b5-1
Apr 2, 2026 (view filing)Apr 11 dayFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$225.00−$450.0K−3.2%60.8K after10b5-1
Mar 11, 2026 (view filing)Mar 92 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$251.03−$1.25M−1.1%466.2K after10b5-1
Mar 5, 2026 (view filing)Mar 41 dayFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$260.22−$520.4K−3.1%62.8K after10b5-1
Mar 3, 2026 (view filing)Mar 21 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$254.30−$254.3K−1.2%84.5K after10b5-1
Feb 10, 2026 (view filing)Feb 91 dayFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$273.78−$1.37M−1.1%466.2K after10b5-1
Feb 6, 2026 (view filing)Feb 42 daysFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$251.31−$502.6K−3.0%64.8K after10b5-1
Feb 6, 2026 (view filing)Feb 42 daysRider Michael JGlobal General CounselSSaleResMed Common Stock−50$260.00−$13.0K−0.5%9.69K after10b5-1
Feb 3, 2026 (view filing)Feb 21 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$257.03−$257.0K−1.2%85.5K after10b5-1
Jan 9, 2026 (view filing)Jan 72 daysFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$248.83−$497.7K−2.9%66.8K after10b5-1
Jan 8, 2026 (view filing)Jan 71 dayFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$248.46−$1.24M−1.1%466.2K after10b5-1
Jan 5, 2026 (view filing)Jan 23 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$241.75−$241.8K−1.1%86.5K after10b5-1
Jan 5, 2026 (view filing)Jan 23 daysRider Michael JGlobal General CounselSSaleResMed Common Stock−50$241.75−$12.1K−0.5%9.74K after10b5-1
Dec 9, 2025 (view filing)Dec 81 dayFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$251.41−$1.25M−1.1%466.2K after10b5-1
Dec 4, 2025 (view filing)Dec 31 dayFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$251.47−$502.9K−2.8%68.8K after10b5-1
Dec 2, 2025 (view filing)Dec 11 dayRider Michael JGlobal General CounselSSaleResMed Common Stock−50$244.16−$12.2K−0.5%9.79K after10b5-1
Dec 2, 2025 (view filing)Dec 11 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$244.16−$244.2K−1.1%87.5K after10b5-1
Nov 26, 2025 (view filing)Nov 251 dayDe Witte JanDirectorSSaleReMed Common Stock−2.06K$255.00−$524.0K−32.5%4.26K after10b5-1
Nov 13, 2025 (view filing)Nov 121 dayFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$252.05−$504.1K−2.9%66.1K after10b5-1
Nov 13, 2025 (view filing)Nov 112 daysDe Witte JanDirectorSSaleReMed Common Stock−487$250.25−$121.9K−8.4%5.32K after10b5-1
Nov 10, 2025 (view filing)Nov 73 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−8.01K$249.75−$2.00M−1.7%467.9K after10b5-1
Nov 4, 2025 (view filing)Nov 31 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−3.00K$247.54−$742.6K−3.4%85.7K after10b5-1
Oct 9, 2025 (view filing)Oct 72 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−8.01K$282.85−$2.27M−1.7%467.8K after10b5-1
Oct 3, 2025 (view filing)Oct 12 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−3.00K$274.36−$823.1K−3.3%86.7K after10b5-1
Oct 2, 2025 (view filing)Oct 11 dayRider Michael JGlobal General CounselSSaleResMed Common Stock−100$274.36−$27.4K−0.9%11.3K after10b5-1
Sep 9, 2025 (view filing)Sep 81 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−8.01K$278.14−$2.23M−1.7%467.8K after10b5-1
Sep 3, 2025 (view filing)Sep 21 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−3.00K$270.77−$812.3K−3.3%87.7K after10b5-1
Aug 19, 2025 (view filing)Aug 181 dayHernandez JohnDirectorSSaleResMed Common Stock−2.58K$287.10−$739.3K−38.9%4.04K after
Aug 11, 2025 (view filing)Aug 74 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−8.01K$279.48−$2.24M−1.7%455.5K after10b5-1
Aug 5, 2025 (view filing)Aug 14 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−3.00K$281.90−$845.7K−3.5%83.3K after10b5-1
Aug 4, 2025 (view filing)Aug 13 daysRider Michael JGlobal General CounselSSaleResMed Common Stock−50$281.90−$14.1K−0.6%8.49K after10b5-1
Jul 9, 2025 (view filing)Jul 72 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−8.01K$256.72−$2.06M−1.7%455.5K after10b5-1
Jul 3, 2025 (view filing)Jul 21 dayFarrell Peter CDirectorSSaleResMed Common Stock−945$255.49−$241.4K−1.4%68.3K after10b5-1
Jul 2, 2025 (view filing)Jul 11 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−3.88K$256.99−$997.9K−4.4%84.3K after10b5-1
Jul 2, 2025 (view filing)Jul 11 dayRider Michael JGlobal General CounselSSaleResMed Common Stock−66$256.99−$17.0K−0.8%8.54K after10b5-1
Jun 10, 2025 (view filing)Jun 91 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−8.01K$251.21−$2.01M−1.7%455.5K after10b5-1
Jun 6, 2025 (view filing)Jun 42 daysFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$247.32−$494.6K−2.8%69.2K after10b5-1
Jun 3, 2025 (view filing)Jun 21 dayRider Michael JGlobal General CounselSSaleResMed Common Stock−41$243.78−$9.99K−0.5%8.87K after10b5-1
Jun 3, 2025 (view filing)Jun 21 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$243.78−$243.8K−1.2%85.3K after10b5-1
May 27, 2025 (view filing)May 225 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−3.64K$244.59−$891.3K−4.1%86.3K after10b5-1
May 22, 2025 (view filing)May 202 daysDe Witte JanDirectorSSaleReMed Common Stock−2.00K$243.47−$486.9K−25.6%5.81K after10b5-1
May 9, 2025 (view filing)May 72 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−8.01K$243.23−$1.95M−1.7%455.5K after10b5-1